facebook

Consistent Bleed Protection That Fits Your Lifestyle

Zero spontaneous bleeds (median AsBR) regardless of
age and dosing schedule in hemophilia A clinical trials

  • Shown in children, adolescents, and adults when treated with AFSTYLA as prophylaxis
  • Overall annualized bleeds (median ABR) was 1.14 in adults and adolescents, and 3.69 in children
purple connector

Proven bleed protection with AFSTYLA twice weekly in adults and adolescents*

ZERO INHIBITORS

Adults and adolescents

ZERO Spontaneous bleeds (median AsBR)

ZERO Annualized bleeds (median ABR)

ZERO Joint bleeds (median AjBR)

*FDA approved for dosing 2 to 3 times a week.

What different ways were
bleeds measured?

  • Annualized spontaneous bleeding rate (AsBR)
    shows the number of spontaneous bleeds, or bleeds that happen without an obvious cause, over a year
  • Annualized bleeding rate (ABR) shows the number of bleeds that happen over a year for any reason
  • Annualized joint bleeding rate (AjBR) shows the number of bleeds that happen over a year in a joint

Dependable bleed control when you need it

On-demand Factor VIII treatment

In clinical trials, the majority of bleeds successfully resolved with 1 infusion

In clinical trials, the majority of bleeds successfully resolved with 1 infusion

On-demand chart: bleeds were controlled with 1 to 2 infusions of AFSTYLA

In the remaining 6% of participants over 12 years old, bleeds were controlled with 3 or more infusions. In children under 12 years old, 3.5% of bleeds were controlled with 3 or more infusions. One child had no response.

Presurgery and postsurgery control

100% of surgeries had excellent or good bleeding control

With AFSTYLA, surgical bleeding control was rated "excellent" in 15 surgeries and "good" in 1 surgery.

You are now leaving the current website.

Do you want to continue?

No Yes